查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1419143

流涎治疗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按药物治疗和最终用户分类

Sialorrhea Treatment Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Medical Therapy and End User
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

根据我们关于「到 2030 年流涎治疗市场预测 - 全球分析 - 按药物治疗和最终用户划分」的最新研究，2022 年市场估值为 6.95 亿美元，预计到 2030 年将达到 10.42 亿美元；预计2022年至2030年CAGR为5.2%。

市场的成长归因于神经退化性疾病的盛行率不断增加以及流涎的各种治疗方案的可用性。此外，不断增加的研发（R＆D）和新药批准可能会推动未来几年流涎治疗市场的成长。然而，与流涎治疗相关的挑战限制了市场的成长。

流涎的治疗包括行为和生活方式咨询、药物、手术和放射。非药物疗法包括姿势建议、控制吞嚥、控制咳嗽、饮食调整、饮食程序和行为改变。然而，这些保守措施可能不适用于患有随着时间推移而恶化的神经系统问题的个体。许多用于治疗流涎的药物也具有抗胆碱能特性，可用于控制流涎过多。阿米替林、丙环利定和利海索就是其中的一些。大多数药物都有合併症（例如不适或睡眠困难）和唾液过多，这使得它们在某些情况下可能有帮助。因此，各种流涎治疗方法的出现预计将在未来几年推动市场成长。

然而，由于患者和医疗保健专业人员对该疾病的无知，慢性流涎的诊断和治疗被延迟。预计这将成为阻碍慢性流涎治疗市场扩张的主要障碍。此外，预计医疗保健专业人员（包括专家和初级保健医生）对持续性流涎作为一种单独的疾病知之甚少。

该报告对流涎治疗市场进行瞭如下细分：

流涎治疗市场根据药物治疗和最终用户分为两部分。市场依医疗分为药物治疗、放射治疗等。依最终使用者划分，流涎治疗市场分为医院、专科诊所、家庭护理机构等。流涎治疗市场依地理位置分为北美（美国、加拿大和墨西哥）、欧洲（法国、德国、义大利、英国、西班牙和欧洲其他地区）、亚太地区（澳洲、中国） 、日本、印度、韩国和亚太地区其他地区）、中东和非洲（沙乌地阿拉伯、阿联酋、南非以及中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷） ，以及南美洲和中美洲的其他地区）

基于医学治疗的见解

依药物治疗，流涎治疗市场分为药物治疗、放射治疗等。 2022年，药物治疗领域占据最大的市场。此外，预计该细分市场从 2022 年到 2030 年将创下最高CAGR。疫苗可提供针对特定传染病的主动获得性免疫力。在多项独立临床试验中，苯托品、格隆溴铵、东莨菪碱和肉毒桿菌毒素等药物治疗已被证明可有效控制流涎。药物经由口服或肠胃外给药。在解剖学外部触诊或超音波检查的引导下将肉毒桿菌注射到唾液腺中。

基于最终用户的见解

依最终使用者划分，流涎治疗市场分为医院、专科诊所、家庭护理机构等。医院细分市场在 2022 年占据最大市场份额，预计 2022-2030 年CAGR最高。流涎的治疗是在医院透过适当的治疗和运动疗法进行的，并在经验丰富的跨学科医学专家（包括物理治疗师和神经病学专家）的帮助下进行。

在准备有关流涎治疗市场的报告时提到的一些主要的主要和次要来源包括世界卫生组织（WHO）和帕金森基金会等。

目录

第 1 章：简介

  • 研究范围
  • 市场定义、假设与限制
  • 市场区隔

第 2 章：执行摘要

  • 重要见解
  • 市场吸引力分析

第 3 章：研究方法

第 4 章：流涎市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链供应商名单

第 5 章：流涎市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驱动因素和限制因素的影响分析

第 6 章：流涎市场 - 全球市场分析

  • 流涎 - 全球市场概览
  • 流涎 - 全球市场与 2030 年预测

第 7 章：流涎市场 - 收入分析 - 按药物治疗，2020-2030 年

  • 概述
  • 药物治疗
  • 放射治疗
  • 其他的

第 8 章：流涎市场 - 收入分析 - 按最终用户，2020-2030 年

  • 概述
  • 医院
  • 专科诊所
  • 家庭护理设置
  • 其他的

第 9 章：流涎市场 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

註 - 将为以下提到的地区/国家提供类似的分析

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 10 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 11 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与专注

第 12 章：流涎市场 - 主要公司概况

  • Supernus Pharmaceuticals, Inc.

注意 - 将为以下公司列表提供类似信息

  • 普罗维卡有限公司
  • 梅尔茨製药股份有限公司。
  • 艾尔建
  • 葛兰素史克
  • 盐野木公司
  • 拜耳公司
  • 诺华製药公司
  • 诺贝尔製药有限公司
  • 百时美施贵宝公司

第 13 章：附录

  • 词彙表
  • 关于 Insight Partners
  • 市场情报云
简介目录
Product Code: TIPRE00033418

According to our latest study on "Sialorrhea Treatment Market Forecast to 2030 - Global Analysis - by Medical Therapy and End User," the market was valued at US$ 0.695 billion in 2022 and is expected to reach US$ 1.042 billion by 2030; it is estimated to record a CAGR of 5.2% from 2022 to 2030.

The market growth is attributed to the increasing prevalence of neurodegenerative disorders and the availability of various treatment options for sialorrhea. Moreover, rising research and development (R&D) and new drug approvals will likely fuel the sialorrhea treatment market growth in the coming years. However, challenges related to sialorrhea treatment restrain the market growth.

Treatments for sialorrhea include behavioral and lifestyle counseling, medication, surgery, and radiation. Nonpharmacological therapies include advice on posture, controlling swallowing, managing cough, dietary adjustments, eating and drinking procedures, and behavioral modification. Nevertheless, these conservative measures might not work for individuals with neurological problems that worsen over time. Many drugs that have been used to treat sialorrhea also have anticholinergic properties that have been utilized to control hypersalivation. Amitriptyline, procyclidine, and rihexyphenidyl are a few of these. Most medications have co-morbidities (such as discomfort or trouble sleeping) and hypersalivation, which makes them potentially helpful in some situations. Therefore, the availability of various treatments for sialorrhea is expected to boost market growth in the coming years.

However, diagnosis and treatment of chronic sialorrhea are delayed due to patient and healthcare professional ignorance about the condition. This is anticipated to be the main obstacle impeding the market expansion for chronic sialorrhea treatments. Furthermore, it is anticipated that healthcare professionals-including specialists and primary care doctors-will know very little about persistent sialorrhea as a separate illness.

The report segments the sialorrhea treatment market as follows:

The sialorrhea treatment market is bifurcated based on medical therapy and end users. The market is segmented by medical treatment into pharmacologic therapy, radiotherapy, and others. The sialorrhea treatment market, by end-user, is segmented into hospitals, specialty clinics, home care settings, and others. The sialorrhea treatment market, based on geography, is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America)

Medical Therapy-Based Insights

Based on medical therapy, the sialorrhea treatment market is segmented into pharmacologic therapy, radiotherapy, and others. In 2022, the pharmacologic therapy segment held the largest market share. Also, the segment is expected to record the highest CAGR from 2022 to 2030. Vaccines provide active acquired immunity against particular infectious diseases. In multiple independent clinical trials, pharmacological treatments such as benztropine, glycopyrrolate, scopolamine, and botulinum toxins have been demonstrated to be effective in managing sialorrhea. Medications are delivered orally or parenterally. Botulinum toxin is injected into the salivary gland guided by anatomical external palpation or ultrasonography.

End User-Based Insights

The sialorrhea treatment market, by end-user, is segmented into hospitals, specialty clinics, home care settings, and others. The hospitals segment held the largest market share in 2022 and is anticipated to record the highest CAGR during 2022-2030. The treatment for sialorrhea is done in hospitals through appropriate treatment and motor therapy, with the help of highly experienced interdisciplinary medical specialists, including physiotherapists and neurology specialists.

A few of the major primary and secondary sources referred to while preparing the report on the sialorrhea treatment market are the World Health Organization (WHO) and the Parkinson's Foundation, among others.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Sialorrhea Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Sialorrhea Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Sialorrhea Market - Global Market Analysis

  • 6.1 Sialorrhea - Global Market Overview
  • 6.2 Sialorrhea - Global Market and Forecast to 2030

7. Sialorrhea Market - Revenue Analysis (USD Million) - By Medical Therapy, 2020-2030

  • 7.1 Overview
  • 7.2 Pharmacologic Therapy
    • 7.2.1 Anticholinergic
    • 7.2.2 Botulinum Toxins
  • 7.3 Radiotherapy
  • 7.4 Others

8. Sialorrhea Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 8.1 Overview
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Homecare Settings
  • 8.5 Others

9. Sialorrhea Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Sialorrhea Market Overview
    • 9.1.2 North America Sialorrhea Market Revenue and Forecasts to 2030
    • 9.1.3 North America Sialorrhea Market Revenue and Forecasts and Analysis - By Medical Therapy
    • 9.1.4 North America Sialorrhea Market Revenue and Forecasts and Analysis - By End User
    • 9.1.5 North America Sialorrhea Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Sialorrhea Market
        • 9.1.5.1.1 United States Sialorrhea Market, by Medical Therapy
        • 9.1.5.1.2 United States Sialorrhea Market, by End User
      • 9.1.5.2 Canada Sialorrhea Market
        • 9.1.5.2.1 Canada Sialorrhea Market, by Medical Therapy
        • 9.1.5.2.2 Canada Sialorrhea Market, by End User
      • 9.1.5.3 Mexico Sialorrhea Market
        • 9.1.5.3.1 Mexico Sialorrhea Market, by Medical Therapy
        • 9.1.5.3.2 Mexico Sialorrhea Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Sialorrhea Market - Key Company Profiles

  • 12.1 Supernus Pharmaceuticals, Inc.
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 12.2 Proveca Ltd
  • 12.3 Merz Pharmaceuticals, LLC.
  • 12.4 Allergan
  • 12.5 GlaxoSmithKline
  • 12.6 Shionogi Inc.
  • 12.7 BAYER INC
  • 12.8 Novartis Pharmaceuticals Corporation
  • 12.9 Nobelpharma Co., Ltd.
  • 12.10 Bristol-Myers Squibb Company

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud